Search | Clinical Trials Finder

Conditions: Osteopetrosis
Interventions: Actimmune Registry; Drug
Lead sponsor: InterMune; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Trifluridine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: 5-Fluorouracil, Leucovorin (LV), Gamma-Interferon-1b (IFN-γ), Bevacizumab; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Interventions: Interferon gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Disease, Macular Disease
Interventions: Interferon gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
Interventions: Ergocalciferol, Sugar pill; Drug · Other
Lead sponsor: Seth I. Sokol, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Advanced Solid Tumors
Interventions: interferon-gamma and nivolumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anterior Uveitis, Uveitis
Interventions: Interferon Gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander, MD; Other
Eligibility: 1 Month to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Basal Cell Carcinoma
Interventions: SP-002, Vismodegib; Drug
Lead sponsor: Stamford Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Boca Raton, Florida • Coral Springs, Florida + 7 more

Conditions: Malignant Mesothelioma
Interventions: recombinant interferon gamma, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, mitomycin C, conventional surgery, hyperthermia treatment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Mycobacterium Avium-Intracellulare Infection
Interventions: Cytokine therapy, Interferon Gamma, GM-CSF; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteopetrosis
Interventions: Interferon gamma-1b; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 1 Year and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Torrance, California • Minneapolis, Minnesota

Conditions: Cystic Fibrosis
Interventions: interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 12 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more

Conditions: Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
Interventions: IFN-γ (interferon gamma-1b) injection; Drug
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bone Marrow Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Granulomatous Disease
Interventions: Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Granulomatous Disease
Interventions: Administration of drug (Interferon-gamma 1-b) subcutaneously; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Friedreich Ataxia
Interventions: Interferon Gamma-1b; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
Interventions: Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Camden, New Jersey + 3 more

Conditions: Hemophagocytic Lymphohistiocytosis
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Grand Rapids, Michigan • Chapel Hill, North Carolina • Cincinnati, Ohio + 1 more

Conditions: Chronic Hepatitis C
Interventions: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin; Drug
Lead sponsor: InterMune; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Lung Disease, Pulmonary Fibrosis
Interventions: interferon-gamma 1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

Vitamin D Repletion in Coronary Artery Disease

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

ACTIMMUNE in Intermediate Osteopetrosis

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Cytokine Gene Polymorphisms in Bone Marrow Failure

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Effect of IFN-γ on Innate Immune Cells

Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)